Nonsurgical Treatment of Nasal Polyps Questions & Answers

1. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010 May. 125(5):1069-1076.e4. [QxMD MEDLINE Link].

2. Martinez-Devesa P, Patiar S. Oral steroids for nasal polyps. Cochrane Database Syst Rev. 2011 Jul 6. CD005232. [QxMD MEDLINE Link].

3. Kirtsreesakul V, Wongsritrang K, Ruttanaphol S. Clinical efficacy of a short course of systemic steroids in nasal polyposis. Rhinology. 2011 Dec. 49(5):525-32. [QxMD MEDLINE Link].

4. Tos M. The pathogenic theories on the formation of nasal polyps. Am J Rhinol. 1990. 4:51-6.

5. Bernstein JM, Gorfien J, Noble B. Role of allergy in nasal polyposis: a review. Otolaryngol Head Neck Surg. 1995 Dec. 113(6):724-32. [QxMD MEDLINE Link].

6. Rudmik L, Schlosser RJ, Smith TL, Soler ZM. Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis. Laryngoscope. 2012 Jul. 122(7):1431-7. [QxMD MEDLINE Link].

7. Becker SS, Rasamny JK, Han JK, Patrie J, Gross CW. Steroid injection for sinonasal polyps: the University of Virginia experience. Am J Rhinol. 2007 Jan-Feb. 21(1):64-9. [QxMD MEDLINE Link].

8. Moss WJ, Kjos KB, Karnezis TT, et al. Intranasal steroid injections and blindness: Our personal experience and a review of the past 60 years. Laryngoscope. 2014 Nov 6. [QxMD MEDLINE Link].

9. Shen J, Welch K, Kern R. Mometasone furoate sinus implant - a new targeted approach to treating recurrent nasal polyp disease. Expert Rev Clin Pharmacol. 2018 Dec. 11 (12):1163-70. [QxMD MEDLINE Link].

10. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015 Apr. 64 (2):121-30. [QxMD MEDLINE Link]. [Full Text].

11. Bachert C, Mannent L, Naclerio RM, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016 Feb 2. 315 (5):469-79. [QxMD MEDLINE Link]. [Full Text].

12. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Sep 19. [QxMD MEDLINE Link].

13. Galletti C, Barbieri MA, Ciodaro F, et al. Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care. Pharmaceuticals (Basel). 2023 Apr 21. 16 (4):[QxMD MEDLINE Link]. [Full Text].

14. Armengot-Carceller M, Gomez-Gomez MJ, Garcia-Navalon C, et al. Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study. Am J Rhinol Allergy. 2020 Nov 5. 1945892420972326. [QxMD MEDLINE Link].

15. Bikhazi NB. Contemporary management of nasal polyps. Otolaryngol Clin North Am. 2004 Apr. 37(2):327-37, vi. [QxMD MEDLINE Link].

16. Dagli M, Eryilmaz A, Besler T, Akmansu H, Acar A, Korkmaz H. Role of free radicals and antioxidants in nasal polyps. Laryngoscope. 2004 Jul. 114(7):1200-3. [QxMD MEDLINE Link].

17. Rinia AB, Kostamo K, Ebbens FA, van Drunen CM, Fokkens WJ. Nasal polyposis: a cellular-based approach to answering questions. Allergy. 2007 Apr. 62(4):348-58. [QxMD MEDLINE Link].

Sanford M Archer, MD, FACS Professor of Surgery and Pediatrics, Medical Director, UK Voice and Swallowing Clinic, Department of Otolaryngology-Head and Neck Surgery, University of Kentucky Chandler Medical Center

Sanford M Archer, MD, FACS is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Rhinologic Society, Kentucky Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Robert M Kellman, MD Professor and Chair, Department of Otolaryngology and Communication Sciences, State University of New York Upstate Medical University

Robert M Kellman, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Head and Neck Society, American Rhinologic Society, Triological Society, American Neurotology Society, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, Medical Society of the State of New York

Disclosure: Nothing to disclose.

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan; Ryte; Neosoma; MI10<br/>Received income in an amount equal to or greater than $250 from: Neosoma; Cyberionix (CYBX)<br/>Received ownership interest from Cerescan for consulting for: Neosoma, MI10.

Eric J Moore, MD, FACS Residency Director, Associate Professor, Department of Otorhinolaryngology-Head and Neck Surgery, Mayo Graduate School of Medicine

Eric J Moore, MD, FACS is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Head and Neck Society, American Academy of Otolaryngology-Head and Neck Surgery, American Cleft Palate-Craniofacial Association

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article